Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ehsanollah Esfandiari

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Biomaterials|June 23, 2009
Induction of cartilage integration by a chondrocyte/collagen-scaffold implantMoreica B Pabbruwe, Ehsanollah Esfandiari, Wael Kafienah, et al.
Dermatology and Therapy|September 6, 2025
Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic DermatitisEmma Guttman-Yassky, Eric Simpson, Ehsanollah Esfandiari, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 31, 2006
TRACP Influences Th1 pathways by affecting dendritic cell functionEhsanollah Esfandiari, Michael Bailey, Christopher R Stokes, et al.
Clinical and Translational Science|March 2, 2021
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy SubjectsEhsanollah Esfandiari, Mary Chen, Glennda Smithson, et al.
Scientific Reports|January 10, 2018
Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohortRosa M Montero, Athula Herath, Ashfaq Qureshi, et al.
American Journal of Clinical Dermatology|January 18, 2024
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic TargetMichael Croft, Ehsanollah Esfandiari, Camilla Chong, et al.
American Journal of Clinical Dermatology|February 10, 2024
Correction to: OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic TargetMichael Croft, Ehsanollah Esfandiari, Camilla Chong, et al.
Archives of Dermatological Research|November 6, 2024
Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimabEmma Guttman-Yassky, Ehsanollah Esfandiari, Hirotaka Mano, et al.
The British Journal of Dermatology|October 4, 2024
Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviewsAndrew Blauvelt, Jennifer Reckleff, Yang Zhao, et al.
Advances in Therapy|January 7, 2024
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b StudyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Biomaterials|June 23, 2009
Induction of cartilage integration by a chondrocyte/collagen-scaffold implantMoreica B Pabbruwe, Ehsanollah Esfandiari, Wael Kafienah, et al.
Dermatology and Therapy|September 6, 2025
Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic DermatitisEmma Guttman-Yassky, Eric Simpson, Ehsanollah Esfandiari, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 31, 2006
TRACP Influences Th1 pathways by affecting dendritic cell functionEhsanollah Esfandiari, Michael Bailey, Christopher R Stokes, et al.
Clinical and Translational Science|March 2, 2021
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy SubjectsEhsanollah Esfandiari, Mary Chen, Glennda Smithson, et al.
Scientific Reports|January 10, 2018
Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohortRosa M Montero, Athula Herath, Ashfaq Qureshi, et al.
American Journal of Clinical Dermatology|January 18, 2024
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic TargetMichael Croft, Ehsanollah Esfandiari, Camilla Chong, et al.
American Journal of Clinical Dermatology|February 10, 2024
Correction to: OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic TargetMichael Croft, Ehsanollah Esfandiari, Camilla Chong, et al.
Archives of Dermatological Research|November 6, 2024
Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimabEmma Guttman-Yassky, Ehsanollah Esfandiari, Hirotaka Mano, et al.
The British Journal of Dermatology|October 4, 2024
Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviewsAndrew Blauvelt, Jennifer Reckleff, Yang Zhao, et al.
Advances in Therapy|January 7, 2024
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b StudyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
Pageof 2